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Abstract: Background: Acute Coronary Syndrome (ACS) can occur in patients with prior coronary artery bypass grafting 
(CABG). In the Gulf Registry of acute coronary events (Gulf RACE), we identified the clinical characteristics and in-
hospital outcomes of these patients. 
Methods: Clinical characteristics and in-hospital outcomes for 461 ACS patients with prior CABG are compared to 7715 
ACS patients without prior CABG enrolled from 64 hospitals in 6 Gulf countries over a 6-month period. 
Results: The overall incidence of ACS with prior CABG was 5.6% out of 8176 patients. The ACS with prior CABG were 
older (63 vs 55 years, P<0.0001), had more history of diabetes (62.3 vs 37.6%, P <0.0001), dyslipidemia (70.3 vs 29.5%, 
P<0.0001), and hypertension (75.7 vs 47.8%, P<0.0001) compared with the non-CABG group. They presented more  
frequently with dyspnea (14.8 vs 9.5%, P<0.0005), non-ST segment elevation myocardial infarction (41.4 vs 31.6%, 
P<0.0001) and echocardiographic evidence of left ventricular dysfunction (49.4 vs 29.8%, P<0.0001) than ACS without 
prior CABG. They had a complicated in-hospital course with more recurrent ischemia (13.9 vs 9.3%, P=0.0011),  
heart failure (24.1 vs 15.7%), and stroke (2.2 vs 0.6%) compared with those without CABG. The in-hospital mortality  
rate was 5.6% in the CABG group compared with 3.5% in the ACS without prior CABG group. After adjusting for  
confounders, prior CABG was independently associated with recurrent ischemia and shock, more in patients presenting 
with ST elevation than non-ST elevation ACS. 
Conclusions: Patients with ACS and prior CABG are a high-risk group with poor outcomes irrespective of their older age 
and comorbidities. They should be identified and treated differently to improve their outcomes.  
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INTRODUCTION 
  Increasing numbers of coronary artery bypass grafting 
(CABG) surgery was reported annually from the mid- to   
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late-1990s in the United States and Europe [1]. Their benefit 
in reducing
  morbidity and mortality is documented [2, 3],
 
with excellent short- and mid-term outcomes despite marked 
change in patient risk profiles and surgeons operating year-
on-year on an increasing number of higher risk patients [4]. 
However, recurrent myocardial ischemia due to progression 
of atherosclerosis in the native coronaries or graft failure   
is common [5]. As a result the global burden of patients   
admitted with prior history of CABG and acute coronary 
syndrome (ACS) has increased in recent years [6].  
  A few high quality prospective controlled studies have 
examined the clinical impact of ACS in patients with prior 
CABG [6-8]. However, none of these studies was performed 
in Middle Eastern Arab countries. We have previously dem-
onstrated that our ACS patients have different characteristics 
and receive less aggressive interventions compared to west-
ern ACS patients, with only a minority of ACS patients un-
dergoing coronary angiography during the index hospitaliza-
tion [9]. The goal of this study was to examine the character-
istics, clinical presentations, treatment, and in-hospital out-
comes of ACS with prior CABG in our region.  
MATERIALS AND METHODOLOGY 
Study Population 
  The Gulf Registry of acute coronary events (Gulf RACE) 
is a 6-month prospective, multinational study of all consecu-
tive patients hospitalized with the final diagnosis of ACS in 
64 centers in 6 Arab Gulf countries (Kuwait, Oman, United 
Arab Emirates, Yemen, Qatar and Bahrain). Patients were 
recruited in a pilot phase starting on 8 May 2006 for 30 days. 
This period was followed by 5 months recruitment starting 
on January 29, 2007. Full details of the methods have been 
previously published [9, 10]. The term ACS included unsta-
ble angina, ST-segment elevation myocardial infarction 
(STEMI) and non-ST-segment elevation myocardial infarc-
tion (NSTEMI). For the purpose of this analysis, we exam-
ined patients with and without history of prior CABG sur-
gery. The study received ethical approval from the institu-
tional ethical bodies in all participating countries. 
Statistical Analysis 
  Continuous variables are presented as median [25
th - 75
th 
percentiles], and compared with the Wilcoxon rank-sum test. 
Categorical variables are presented as percentages, and com-
pared with the Chi-square test. Multivariate logistic regres-
sion examined the association between prior CABG and in-
hospital outcomes adjusting for baseline characteristics that 
were significantly different at the univariate level between 
the 2 cohorts (with vs without prior CABG). To assess 
whether type of ACS (e.g. STEMI) modified the relationship 
between prior CABG and in-hospital outcomes, we tested for 
interaction with ACS type in the association between prior 
CABG and in-hospital outcomes. All associations from the 
logistic regression models are quantified as odds ratios (OR) 
with 95% confidence intervals (CI). SAS 9.1 statistical pack-
Table 1.  Baseline Patient Characteristics and Comorbidities of the Study Cohort 
  ACS without Prior CABG (n = 7,715)  ACS with Prior CABG (n = 461)  P 
Demographics 
Age, in years (range) 
 
55 [47 – 64] 
 
63 [56 – 70] 
 
< 0.0001 
Male %  76.0   71.4   0.03 
Past Medical History (%) 
Angina 
 
37.7 
 
86.6  
 
< 0.0001 
MI  21.8   66.8  < 0.0001 
PCI   10.5   32.5   < 0.0001 
Risk Factors (%) 
Current smoker (within a year)  
 
37.8 
 
14.8  
 
< 0.0001 
DM I   1.5  2.6  0.0726 
DM II  37.6  62.3  < 0.0001 
Hypertension   47.8   75.7  < 0.0001 
Dyslipidemia 29.5  70.3  <  0.0001 
Comorbidities (%) 
COPD 
 
5.1 
 
8.9 
 
0.0012 
Stroke 4.3  9.5  <  0.0001 
Dialysis 0.9  2.0  0.047 
PAD 2.0  9.5  <  0.0001 
MI: myocardial infarction, PCI: percutanous coronary intervention, DM: diabetes mellitus, COPD: chronic obtructive pulmonary disease, PAD: periphral arterial disease. 198    The Open Cardiovascular Medicine Journal, 2011, Volume 5  Alanbaei et al. 
age (SAS Institute, Cary, NC, USA) was used for all analy-
ses and a P < 0.05 was considered significant. 
RESULTS 
  We enrolled 8,176 consecutive patients with ACS, of 
which 461 patients (5.6%) had prior CABG. Patients with 
prior
 CABG had significantly more adverse baseline charac-
teristics than those without CABG (Table 1). When com-
pared with non-CABG ACS patients, ACS patients with 
prior CABG were older [63 vs 55 years, p<0.0001], and sig-
nificantly more likely to have had a prior history of angina, 
myocardial infarction (MI) and percutanous coronary inter-
vention (PCI) [86.6 vs 37.7%; 66.8 vs 21.8%; 32.5 vs 10.5%, 
respectively, p<0.0001]. They were more likely to be type 2 
diabetic, hypertensive and dyslipidemic [62.3 vs 37.6%; 75.7 
vs 47.8%; 70.3 vs 29.5%, respectively, p< 0.0001]. Comor-
bidities including previous stroke and peripheral arterial dis-
ease were more prevalent in the CABG group compared with 
the non-CABG group [9.5 vs 4.3%; 9.5 vs 2.0% respectively, 
p<0.0001]. CABG patients had also more chronic obstruc-
tive pulmonary disease (COPD) [8.9 vs 5.1%, p=0.001] and 
were more likely to have been on dialysis [2.0 vs 0.9%, 
p=0.046].  
 Table  2 summarizes the data on clinical presentation and 
investigations. ACS patients with prior CABG were more 
likely to present with advanced Killip class II-IV (33.1 vs 
21.1%, P < 0.0001) compared to ACS without prior CABG. 
Compared to the non-CABG patients, the CABG patients 
were more likely to present with UA and NSTEMI (46.6 vs 
27.6%; 41.4 vs 31.6% respectively, p<0.0001). In addition, 
ACS patients with prior CABG were more likely to have left 
ventricular dysfunction (LVEF  40%: 49.4 vs 29.8%, P < 
Table 2.  Baseline Clinical Presentations, Investigations and Discharge Diagnosis of Study Cohort 
  ACS without Prior CABG  ACS with Prior CABG  P 
Presentation (%) 
Ischemic type chest pain 
 
79.7 
 
73.1 
 
0.001 
Atypical chest pain   6.6  5.9  0.63 
Dyspnea 9.5  14.8  0.0005 
Cardiac arrest  2.4  2.8  0.53 
BP Mean (SD) mmHg      
 Systolic  138 [120 - 160]  137 [120 - 160]  0.55 
 Diastolic  80 [70 - 95]  80 [70 - 90]  < 0.0001 
Heart rate (mean)   83 [70 - 98]  80 [70 - 97]  0.20 
Killip Classification (%)     <  0.0001 
Killip I  78.9  66.9   
Killip II-IV  21.1  33.1   
Echocardiographic findings 
Echocardiogram done (%) 
 
61.9 
 
51.5 
 
< 0.0001 
LVEF  40%  29.8  49.4  < 0.0001 
Discharge Diagnosis (%) 
STEMI 
 
39.6 
 
8.9 
 
< 0.0001 
NSTEMI 31.6  41.4  <  0.0001 
UA 27.6  46.6  <  0.0001 
LBBB MI  1.2  3.0  0.002 
Lab. Investigations 
Total cholesterol (mg/dL) 
 
4.6 [3.5-5.6] 
 
4.3 [3.5-5.3] 
 
< 0.0001 
LDL (mg/dL)  3.1 [2.4-4.0]  2.8 [2.2-3.7]  < 0.0001 
HDL (mg/dL)  1.0 [0.8-1.2]  0.9 [0.8-1.2]  0.11 
Triglycerides (mmol/L)  1.6 [1.1–2.3]  1.5 [1.1– 2.3]  0.54 
Creatinine (mol/L)  88 [62-106]  97 [70-123]  < 0.0001 
LVEF: left ventricular ejection fraction, STEMI: ST segment elevation myocardial infarction, NSTEMI: non ST segment elevation myocardial infarction, UA: unstable angina, 
LBBB MI: left bundle branch block myocardial infarction, LDL: Low-density lipoprotein cholesterol, HDL: High-density lipoprotein cholesterol. Acute Coronary Syndrome with Prior Bypass Surgery  The Open Cardiovascular Medicine Journal, 2011, Volume 5    199 
0.0001). On initial laboratory testing, the CABG patients 
tested with significantly lower levels of total and low-density 
lipoprotein (LDL) cholesterol and higher serum creatinine 
levels (P < 0.05). 
  Treatment patterns are presented in Table 3. For STEMI 
patients, approximately half of those with prior CABG re-
ceived thrombolytic therapy (48.7%) with no significant dif-
ference between the CABG and non-CABG groups (P > 
0.05). During the first 24 h following admission, CABG pa-
tients were more likely to be treated with angiotensin con-
verting enzyme inhibitors/angiotensin receptor blockers 
(ACEI/ARB) (75.1 vs 67.3%, P< 0.05); diuretics (45.5 vs 
24.2%, P < 0.0001) and nitrates (89.3 vs 80.8%, P < 0.0001) 
than patients without prior CABG, and slightly less likely to 
be treated with aspirin, beta-blockers and heparin. At the 
time of discharge, patients with prior CABG were less likely 
to be discharged on aspirin and beta-blockers, but more 
likely to be discharged on statins, nitrates and diuretics. Prior 
CABG patients compared with non-CABG patients under-
went fewer coronary angiograms during the index hospitali-
zation (15.9 vs 12.1%, P > 0.05) (Table 3). 
  ACS patients with CABG suffered more episodes of re-
current ischemia (Table 4) (13.9 vs 9.3%, P < 0.05), heart 
failure (24.1 vs 15.7%, P < 0.0001), and requiring ventilator 
support (8.3 vs 4.6%, P < 0.05). They received more 
inotropic support (11.5 vs 7.4%, P < 0.001), had higher rates 
of major bleeds (2.2 vs 0.6%, P < 0.05), strokes (2.2 vs 
0.6%,  P < 0.0001) and in-hospital mortality rate (5.6 vs 
3.5%, P < 0.05) than the non-CABG patients. 
  In univariate analyses, patients with prior CABG were 
significantly more likely to have adverse events during their 
admission for ACS with significantly higher rates of recur-
rent ischemia, heart failure, requirement for mechanical ven-
tilation and inotropic support, major bleeding, stroke and 
death (Table 4). After adjusting for differences in baseline 
characteristics
  and ACS type (Table 5), prior CABG was 
associated with about a 4-fold increased risk of recurrent 
Table 3.  Treatment Patterns for ACS Patients with and without Prior CABG 
  ACS without Prior CABG %   ACS with Prior CABG %   P 
Coronary reperfusion in STEMI patients* 
Thrombolytic therapy 
 
59.8 
 
48.7 
 
0.16 
Door to needle time (min)  45 [30 - 74]  64 [15 - 100]  0.64 
Primary angioplasty  5.7 0  0.12 
Door to balloon time (min)  75 [60 - 120]  .  . 
Medications in the First 24 h (%) 
Aspirin 
 
97.9  
 
96.5  
 
0.047 
Clopidogrel 53.2  56.0    0.25 
Beta-blocker  65.3   60.5   0.034 
ACE-I/ARB  67.3   75.1   0.0005 
Statins  89.1   92.0   0.053 
Heparin (unfractionated/LMWH)  92.5   89.9   0.049 
Nitrates 80.8  89.3  <  0.0001 
Diuretics  24.2   45.5   < 0.0001 
Medications at Discharge (%) 
Aspirin 
 
94.1  
 
90.4  
 
0.002 
Clopidogrel  49.6   50.1   0.58 
Beta-blocker  75.5   67.0   < 0.0001 
ACE-I/ARB  74.3   77.3   0.16 
Statin  80.3   87.2   0.0003 
Nitrates  68.5   81.3   < 0.0001 
Diuretics  23.4   46.3   < 0.0001 
Angiogram (onsite or after transfer)  19.6  15.9  0.045 
STEMI: ST segment elevation myocardial infarction, LMWH: low molecular weight heparin, ACE-I/ARB: angiotensin converting enzyme inhibitor/angiotensin receptor blocker.  
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ischemia and more than 2-fold increased risk of cardiogenic 
shock among patients with STEMI but not in patients NSTE-
ACS (P for interaction <0.0001 and 0.0087, respectively). 
There was a trend for significant association between history 
of CABG and increased risk of death (OR 1.55, 95%CI 0.95-
2.54, P=0.08). 
DISCUSSION 
  Patient with prior CABG can develop acute coronary 
syndrome (ACS) [3, 11],
 with increasing numbers observed 
in recent years [5, 12-14]. Angiographic studies have dem-
onstrated that vein graft occlusion and disease progression 
are temporally related to ACS.  Between 10 and 15 years 
following surgery only 50-60% of vein grafts remain patent. 
Of these patent grafts, 45% showed angiographic evidence 
of atherosclerosis. Furthermore, 70% of these lesions reduce 
the graft lumen diameter by 50% or more [15-17].
 
  The goal of the present analysis was to determine the 
clinical impact of ACS on a Middle Eastern cohort of pa-
tients with prior CABG. We found ACS patients with prior 
CABG were older and suffered from significantly more ad-
verse comorbidities than the non-CABG ACS group. Stroke 
and PAD were more common, and the prior-CABG group 
had higher rates of angina, infarction and PCI suggesting that 
ACS CABG patients had a greater degree of coronary artery 
disease and generalized atherosclerosis. In addition, diabetes 
mellitus, hypertension and dyslipidemia were more prevalent 
in this cohort. Our clinical findings are consistent with and 
confirm those from other reports [6, 8, 13, 18]; though 
among Middle Eastern patients our study uncovered a higher 
frequency of hypertension and diabetes than previously ob-
served elsewhere [6-8, 19].  
  Although ACS patients with prior CABG in the Gulf 
RACE presented more frequently with NSTEMI, heart fail-
Table 4.  In-Hospital Course and outcomes for ACS Patients with and without Prior CABG 
  ACS without Prior CABG % [n]  ACS with Prior CABG % [n]  P 
Recurrent ischemia   9.3   13.9   0.001 
Infarction/ Reinfarction   2.5   2.2   0.68 
Heart failure   15.7   24.1   < 0.0001 
Ventilation  4.6   8.3   0.0005 
IABP use   0.7   0.7  0.99 
Inotrope  7.4   11.5   0.001 
Cardiogenic shock   5.0   7.0   0.059 
Acute MR   1.0   0.9   0.82 
VSD/LV Rupture   0.1   0.2   0.47 
Major bleeding   0.6   2.2   0.0002 
Stroke  0.6   2.2   < 0.0001 
Death  3.5   5.6   0.019 
IABP: intraaortic balloon pump, MR: mitral regurgitation, VSD/LV: ventricular septal defect/left ventricle. 
 
Table  5.  Adjusted in-Hospital outcomes in Patients with Acute Coronary Syndrome and Prior CABG Compared with those   
without Prior CABG 
In-Hospital Outcome  Odds Ratio  95% CI  P   Interaction P 
Death  1.55  0.95 – 2.54  0.08  0.096 
Recurrent ischemia  STEMI 4.08 
NSTE-ACS 0.94 
2.27-7.33 
0.66-1.33 
0.0004 
NS 
< 0.0001 
Cardiogenic shock  STEMI 2.75 
NSTE-ACS 0.85 
1.45-5.21 
0.46-1.59 
<0.0001 
NS 
0.009 
Stroke  2.72  1.19 – 6.21  0.017  0.21 
Major bleeding  3.03  1.33- 6.87  0.008  0.17 
*The odds ratios are adjusted for age, gender, creatinine, ACS type (STEMI/LBBB MI vs NSTE-ACS) and all comorbidities, NS: non-significant. Acute Coronary Syndrome with Prior Bypass Surgery  The Open Cardiovascular Medicine Journal, 2011, Volume 5    201 
ure and ventricular dysfunction than those without prior 
CABG, the rate of coronary catheterization during the index 
hospitalization was low compared to other studies [20]. 
  Patients with prior CABG also had a more complicated 
in-hospital course with frequent episodes of recurrent ische-
mia, heart failure, major bleeding, and stroke. Thrombolysis 
was used more often than reported in other registries [6], and 
almost half the CABG patients and 60% of the non-CABG 
patients with STEMI had thrombolysis. In comparison, in the 
GRACE Registry [21] one-third of the patients with STEMI 
did not undergo reperfusion therapy. Reperfusion therapy 
was less likely to be used on angina-free patients, the elderly 
and those with diabetes, heart failure, or a previous MI or 
CABG. In our study, contrary to our expectations, the ACS 
patients with prior CABG underwent fewer catheterizations 
during the index hospitalization than those without prior 
CABG.  
  Our data showed that history of prior CABG surgery is 
independently associated with a higher risk of recurrent 
ischemia, shock, bleeding and stroke after adjusting for base-
line variables. Moreover, prior CABG was associated with 
high risk of shock and recurrent ischemia in patients present-
ing with STEMI and not in non-ST elevation MI. This could 
suggests that the mechanism of acute MI in prior CABG 
patients maybe different and needs aggressive reperfusion 
and revascularization therapy. In a study by Grines et al., 
acute MI in patients with prior CABG was mainly due to 
thrombotic occlusion of a saphenous vein graft and conven-
tional thrombolytic therapy may not be sufficient [22].  
  Compared with the 5 other studies (Table 6) [6-8, 18, 
20],
  our Registry had the smallest percentage of coronary 
angiography and intervention during the index hospitaliza-
tion of patients with ACS and prior CABG. We found a   
significantly different distribution of risk factors compared 
with Western data. In our study, diabetes and hypertension 
were the highest observed comorbid conditions among all   
6 groups while smoking and dyslipidemia were in the mid-
range. The observed mortality in our group of 461 patients 
was in the mid-range of study results. Our in-hospital death 
rate was 5.6% while in the other studies it ranged from 1.7 to 
10.7%, nonetheless how the comorbidities affect mortality 
should still be examined.  
  ACS patients with prior CABG are a high-risk group and 
require special attention to decrease and prevent morbidity 
and mortality. They have different demographic characteris-
tic, noteworthy risk factors, a significant past CAD history, 
and multiple comorbidities. We found that this patient group 
is evaluated less aggressively. Mortality rates are increased 
in this patient type probably due to higher prevalence of   
comorbidities, more generalized degree of atherosclerosis 
and less aggressive intervention.  
  Several limitations should be considered. First, angi-
ographic assessment of all patients, an important factor in the 
decision-making for patients who are not amenable for any 
further revascularization due to the aggressiveness of dis-
ease, is not known. Second, neither the time of the CABG 
surgery nor the type of vessel used (arterial or venous graft) 
is known making it impossible to assess the graft patency 
rate. Thirdly, eventhough its known that age and several risk 
factor like diabetes, hypertension and dyslipidemia nega-
tively affect the patency rate of CABG we don’t have that 
data available. Despite these limitations, our findings were 
derived from a prospectively defined analysis of a large 
multi-centre registry and have important implications for 
management of ACS patients in real life. 
CONCLUSIONS 
  Among the Gulf RACE cohort a history of prior CABG 
appears to have an important effect on prognosis in those 
who subsequently develop an ACS. Identifying this high- 
risk group will help improve treatment and prevention in the 
future.  
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Table 6.  Comparison of Gulf RACE with other Studies 
Study 
Number 
(%) 
Death at 30 Days 
(%) 
Smoking 
(%) 
DM 
(%) 
HTN 
(%) 
Dyslipid 
(%) 
Angiogram 
(PCI) % 
Brilakis et al. [7] 
640 
(7.4%) 
8.1 21  29  69 
84 
Prove-it 
?  
(20) 
Labinaz et al. [18] 
1784 
(4%) 
10.7 29.8  17.8  45.7  -- 
62 
(31) 
Labinaz et al. [8] 
1134 
(12%) 
5.2 18  32  62  58 
63 
(29) 
Berry et al. [6] 
1026 
(6.9%) 
4.6 21  38  64  46 
48 
(26) 
Elbarasi et al. [20] 
1193 
(9.6%) 
1.7  
(in-Hosp) 
15.3 37.4  68.5  75.2 
45.2 
(18) 
Our Registry 
461 
(5.6%) 
5.6  
(in-Hosp) 
14.8 62.3  75.7  70.3 
15.9 
(Unknown) 202    The Open Cardiovascular Medicine Journal, 2011, Volume 5  Alanbaei et al. 
FUNDING 
  Gulf RACE is a Gulf Heart Association project and was 
financially supported by sanofi aventis and Qatar Telecom-
munications Company. The sponsors had no role in   
study design, data collection or data analysis. The sponsors 
had no role in the writing of the report and submission of the 
manuscript.  
REFERENCES 
[1]  Ferguson TB Jr, Hammill BG, Peterson ED, DeLong ER, Grover 
FL. A decade of change--risk profiles and outcomes for isolated 
coronary artery bypass grafting procedures, 1990-1999: a report 
from the STS National Database Committee and the Duke Clinical 
Research Institute. Society of Thoracic Surgeons. Ann Thorac Surg 
2002; 73: 480-9. 
[2]  Long-term results of prospective randomised study of coronary 
artery bypass surgery in stable angina pectoris. European Coronary 
Surgery Study Group. Lancet 1982; 2: 1173-80. 
[3]  Varnauskas E. Twelve-year follow-up of survival in the 
randomized European Coronary Surgery Study. N Engl J Med 
1988; 319: 332-7. 
[4]  The Society for Cardiothoracic Surgery in Great Britain and 
Ireland. Sixth National Adult Cardiac Surgical Database Report: 
Demonstrating Quality. 2008. http: //www.scts.org/documents/ 
PDF/Sixth NACSD report 2008 with c.pdf (Accessed 30/10/2010). 
[5]  Rogers WJ, Canto JG, Lambrew CT, et al. Temporal trends in the 
treatment of over 1.5 million patients with myocardial infarction in 
the US from 1990 through 1999: the National Registry of 
Myocardial Infarction 1, 2 and 3. J Am Coll Cardiol 2000; 36: 
2056-63. 
[6]  Berry C, Pieper KS, White HD, et al. Patients with prior coronary 
artery bypass grafting have a poor outcome after myocardial 
infarction: an analysis of the VALsartan in acute myocardial 
iNfarcTion trial (VALIANT). Eur Heart J 2009; 30: 1450-6. 
[7]  Brilakis ES, de Lemos JA, Cannon CP, et al. Outcomes of patients 
with acute coronary syndrome and previous coronary artery bypass 
grafting (from the Pravastatin or Atorvastatin Evaluation and 
Infection Therapy [PROVE IT-TIMI 22] and the Aggrastat to 
Zocor [A to Z] trials). Am J Cardiol 2008; 102: 552-8. 
[8]  Labinaz M, Kilaru R, Pieper K, et al. Outcomes of patients with 
acute coronary syndromes and prior coronary artery bypass 
grafting: results from the platelet glycoprotein IIb/IIIa in unstable 
angina: receptor suppression using integrilin therapy (PURSUIT) 
trial. Circulation 2002; 105: 322-7. 
[9]  Zubaid M, Rashed WA, Almahmeed W, et al. Management and 
outcomes of Middle Eastern patients admitted with acute coronary 
syndromes in the Gulf Registry of Acute Coronary Events (Gulf 
RACE). Acta Cardiol 2009; 64: 439-46. 
[10]  Zubaid M, Rashed WA, Al-Khaja N, et al. Clinical presenta- 
tion and outcomes of acute coronary syndromes in the gulf registry 
of acute coronary events (Gulf RACE). Saudi Med J 2008; 29:   
251-5. 
[11]  Sabik JF, 3rd, Blackstone EH, Gillinov AM, Smedira NG, Lytle 
BW. Occurrence and risk factors for reintervention after coronary 
artery bypass grafting. Circulation 2006; 114: I454-60. 
[12]  Babaev A, Frederick PD, Pasta DJ, Every N, Sichrovsky T, 
Hochman JS. Trends in management and outcomes of patients with 
acute myocardial infarction complicated by cardiogenic shock. 
JAMA 2005; 294: 448-54. 
[13]  Goldberg RJ, Currie K, White K, et al. Six-month outcomes in a 
multinational registry of patients hospitalized with an acute 
coronary syndrome (the Global Registry of Acute Coronary Events 
[GRACE]). Am J Cardiol 2004; 93: 288-93. 
[14]  Granger CB, Goldberg RJ, Dabbous O, et al. Predictors of hospital 
mortality in the global registry of acute coronary events. Arch 
Intern Med 2003; 163: 2345-53. 
[15]  Bourassa MG, Enjalbert M, Campeau L, Lesperance J. Progression 
of atherosclerosis in coronary arteries and bypass grafts: ten years 
later. Am J Cardiol 1984; 53: 102C-7C. 
[16]  Fitzgibbon GM, Kafka HP, Leach AJ, Keon WJ, Hooper GD, 
Burton JR. Coronary bypass graft fate and patient outcome: 
angiographic follow-up of 5,065 grafts related to survival and 
reoperation in 1,388 patients during 25 years. J Am Coll Cardiol 
1996; 28: 616-26. 
[17]  Goldman S, Zadina K, Moritz T, et al. Long-term patency of 
saphenous vein and left internal mammary artery grafts after 
coronary artery bypass surgery: results from a Department of 
Veterans Affairs Cooperative Study. J Am Coll Cardiol 2004; 44: 
2149-56. 
[18]  Labinaz M, Sketch MH Jr, Ellis SG, et al. Outcome of acute ST-
segment elevation myocardial infarction in patients with prior 
coronary artery bypass surgery receiving thrombolytic therapy. Am 
Heart J 2001; 141: 469-77. 
[19]  Franklin K, Goldberg RJ, Spencer F, et al. Implications of   
diabetes in patients with acute coronary syndromes. The Global 
Registry of Acute Coronary Events. Arch Intern Med 2004; 164: 
1457-63. 
[20]  Elbarasi E, Goodman SG, Yan RT, et al. Management patterns of 
non-ST segment elevation acute coronary syndromes in relation to 
prior coronary revascularization. Am Heart J 2010; 159: 40-6. 
[21]  Eagle KA, Goodman SG, Avezum A, Budaj A, Sullivan CM, 
Lopez-Sendon J. Practice variation and missed opportunities for 
reperfusion in ST-segment-elevation myocardial infarction: 
findings from the Global Registry of Acute Coronary Events 
(GRACE). Lancet 2002; 359: 373-7. 
[22]  Grines CL, Booth DC, Nissen SE, et al. Mechanism of acute 
myocardial infarction in patients with prior coronary artery bypass 
grafting and therapeutic implications. Am J Cardiol 1990; 65: 
1292-6. 
 
 
Received: June 30, 2011  Revised: July 22, 2011  Accepted: July 25, 2011 
 
© Alanbaei et al.; Licensee Bentham Open. 
 
This is an open access article licensed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/ 
by-nc/3.0/) which permits unrestricted, non-commercial use, distribution and reproduction in any medium, provided the work is properly cited.  
 
 
 